Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
GB100
- Development stage
- Unknown
- Lead developer
- Galleon Bio
- Modality
- Small Molecules
- Administration
- Topical
01
Overview
GB100 is a topical small molecule therapeutic candidate developed by Galleon Bio, currently in Phase 2 clinical development for the treatment of radiodermatitis (RD) and chemotherapy-induced peripheral neuropathy (CIPN). The formulation is based on strontium nitrate. Strontium ions (Sr2+) are known to act as selective inhibitors of sensory nerve activation, specifically targeting type C nociceptors that transmit pain and itch signals. By modulating these nociceptive pathways, GB100 aims to provide localized relief from the skin irritation and neuropathic pain associated with cancer treatments without the systemic side effects or skin thinning often seen with corticosteroids.
- Other names
- elemental strontium
Beyond the preview
Go deeper on GB100.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on GB100.